Vonseca

Brand Name: Vonseca Tablet.

Composition:

Each Vonseca 10mg tablet contains: vonoprazan ................................................. 10 mg.

Each Vonseca 20mg tablet contains: vonoprazan ...........................................20mg.

Therapeutic Indications:                 

• Treatment of gastroesophageal reflux disease.
• Treatment of Helicobacter pylori infection.

Dosage and Administration:   

• Reflux oesophagitis.

○          Adult: 20 mg once daily for 4 weeks, may be followed by a further 4 weeks if necessary. Maintenance therapy of healing in patients with repeat recurrence or relapse: 10 mg once daily, may be increased to 20 mg once daily if needed.

• Gastric ulcer

○          Adult: 20 mg once daily for 8 weeks.

• Prophylaxis of NSAID-induced ulcers

○          Adult: Including cases that occur during low-dose aspirin therapy: 10 mg once daily.

• Duodenal ulcer

○          Adult: 20 mg once daily for 6 weeks.

• Eradication of H. pylori associated with peptic ulcer disease
  • Adult: Adjunct in the triple therapy regimen with antibiotics: 20 mg bid for 7 days in combination with amoxicillin and clarithromycin. Alternatively, 20 mg bid may be given for 7 days in combination with amoxicillin and metronidazole.

Contraindications:  

• Concomitant use with atazanavir and rilpivirine.

Warnings and precautions:            

• May mask symptoms of gastric malignancy.
• Renal and hepatic impairment.
• Pregnancy.

Undesirable Effects:       

• Significant: Clostridium difficile-associated infection, pseudomembranous colitis, increased intragastric pH, benign gastric polyps (prolonged use); increased risk of hip, spine, or wrist osteoporosis-related fractures (long-term use or high doses); hepatic function abnormalities, including liver injury. Rarely, hypomagnesaemia (prolonged use).
• Gastrointestinal disorders: Diarrhea, constipation, nausea, abdominal distention or discomfort, stomatitis, taste abnormality.
• Hepatobiliary disorders: Jaundice.
• Immune system disorders: Hypersensitivity reactions (e.g. urticaria, anaphylactic shock).
• Investigations: Increased AST, ALT, and gamma-glutamyl transferase.
• Skin and subcutaneous tissue disorders: Rash, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, drug eruption

Pharmacological Properties:

Vonoprazan is a potassium-competitive acid blocker (PCAB). It competitively inhibits the binding of K ions to hydrogen/potassium-adenosine triphosphate (H+/K+-ATPase) enzyme system that acts as the proton pump of the gastric parietal cell, thereby inhibiting gastric acid production belong to the proton pump inhibitor group is a medication which reduces stomach acid.

Packaging:              

Vonseca 10mg Tablet: Box containing 2 blisters of 10 tablets each.

Vonseca 20mg Tablet: Box containing 2 blisters of 10 tablets each.